AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pharmaceutical Companies

650.541

-4.208-0.64%

Number of Gainers:18

Number of Losers:7

Number of Flat:20

PE:- -

High:656.360

Open:654.803

Low:648.837

Close:654.584

Volume:15.47M

Turnover:24.36M

Market Cap:97.22B

Float Cap:94.18B

Loading ...

Patrys Ltd-Changes to Board, Company Secretary and Office Address

THOMSON REUTERS

Imricor Medical Systems Inc-Imricor Appoints Aldo Denti to Board of Directors

THOMSON REUTERS

Hexcel (HXL): Evaluating Valuation After Recent Share Gains and Buyback Announcement

Simply Wall St.

Gold X2 Advances Environmental Studies for Moss Gold Project in Ontario

Dimerix to Benefit from Filpari's Approval, But Nothing to Lose from Rejection, Says Euroz Hartleys

MT Newswires Live

Mayne Pharma - Asic Formally Granted Co an Extension of Time to Hold Its 2025 AGM From on or Before 28 Nov to on or Before 30 Jan

THOMSON REUTERS

Mayne Pharma Group Ltd - Extension of Time to Hold Annual General Meeting

THOMSON REUTERS

September 'Painful' Month for Long-Term Quality Growth Investors, Says BofA

MT Newswires Live

Grassroots leagues revive China's soccer dream

BRIEF-Mayne Pharma Group Updates On Status Of FIRB Approval

Mayne Pharma Group Ltd - Firb Extends Deadline for Approval to 14 November 2025

THOMSON REUTERS

High Growth Tech Stocks in Australia for November 2025

Simply Wall St.

Immuron Limited Announces US$8.5 Million Share Placement to US Investors

Haemonetics reports second quarter revenue of $327 million and earnings per diluted share of $0.81

BRIEF-Australian Government Takeovers Panel Receives Application From Mayne Pharma

Australia's Takeovers Panel - No Decision Has Been Made Whether to Conduct Proceedings

THOMSON REUTERS

Australia's Takeovers Panel - Mayne Seeks Final Orders, Including Cosette Agree to Extend Statutory Deadline for Firb's Determination to 1 Dec

THOMSON REUTERS

Australian Govt Takeovers Panel - Receives Application From Mayne Pharma Group

THOMSON REUTERS

Australia's Takeovers Panel - Mayne Seeks Interim Orders, Including Cosette Confirm to the Panel That It Will Meet With Firb

THOMSON REUTERS

Proteomics International Receives AU$500,000 Western Australia Grant to Help Commercialize Endometriosis Blood Test

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK7508/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":650.3763,"timestamp":1762731935370,"preClose":654.584,"halted":0,"volume":15458058,"delay":0,"changeRate":-0.006428,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-4.207703,"latestTime":"11-10 10:45:42 AEDT","open":654.80316,"high":656.3603,"low":648.8371,"amount":24355640,"amplitude":0.011493,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1762750800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1762729200000,1762750800000]],"turnoverRate":0.000594,"increases":19,"decrements":8,"flats":17,"marketCap":97222842041,"floatMarketCap":94179377524.625},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":656.3603,"amplitude":0.011493,"preClose":654.584,"low":648.8371,"latestPrice":650.5412,"volume":15467410,"delay":0,"open":654.80316,"prevYearClose":936.801,"prevWeekClose":654.584,"prevMonthClose":662.953,"prevQuarterClose":712.826,"fiveDayClose":650.95,"twentyDayClose":751.072,"sixtyDayClose":937.392,"secType":"PLATE","market":"AU","turnoverRate":0.000594,"marketCap":97222842041,"floatMarketCap":94179377524.625,"timestamp":1762731941245,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":18,"down":7,"flat":20},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2582169818","title":"Patrys Ltd-Changes to Board, Company Secretary and Office Address","url":"https://stock-news.laohu8.com/highlight/detail?id=2582169818","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582169818?lang=en_us&edition=fundamental","pubTime":"2025-11-10 06:03","pubTimestamp":1762725792,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251109:nTUE74MSFR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","PAB.AU"],"gpt_icon":0},{"id":"2582816521","title":"Imricor Medical Systems Inc-Imricor Appoints Aldo Denti to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2582816521","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582816521?lang=en_us&edition=fundamental","pubTime":"2025-11-10 05:54","pubTimestamp":1762725276,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251109:nTUEKLLKV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7007","BK7503","BK7508","IMR.AU"],"gpt_icon":0},{"id":"2582816273","title":"Hexcel (HXL): Evaluating Valuation After Recent Share Gains and Buyback Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2582816273","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582816273?lang=en_us&edition=fundamental","pubTime":"2025-11-10 05:21","pubTimestamp":1762723267,"startTime":"0","endTime":"0","summary":"Hexcel (HXL) has delivered steady returns over the past year, with shares rising about 13%. Investors might be wondering what factors could be at play as the stock continues its upward trend this month.\nSee our latest analysis for Hexcel.\nHexcel’s momentum has picked up lately, with a notable 11.4% share price return over the past month and a solid one-year total shareholder return of 13.3%. This gain adds to a longer-term track record of steady performance, suggesting growing investor...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/3021000-choice1-main-header/1585186644732","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3021000-choice1-main-header/1585186644732"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-hxl/hexcel/news/hexcel-hxl-evaluating-valuation-after-recent-share-gains-and","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-hxl/hexcel/news/hexcel-hxl-evaluating-valuation-after-recent-share-gains-and","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0053671581.USD","HXL","LU0240878834.USD","LU0240877869.USD","LU0205193047.USD","BK7067","LU0205194284.USD","HXL.AU","BK7508","BK4187"],"gpt_icon":0},{"id":"2581022400","title":"Gold X2 Advances Environmental Studies for Moss Gold Project in Ontario","url":"https://stock-news.laohu8.com/highlight/detail?id=2581022400","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581022400?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:01","pubTimestamp":1762516913,"startTime":"0","endTime":"0","summary":"Gold X2 Mining Inc. has announced a significant update on the environmental baseline studies for its Moss Gold Project in Northwest Ontario, Canada. The studies, which began in 2021 and have expanded through 2025, are a key part of the company's strategy to de-risk the project from an environmental permitting perspective. Led by CSL Environmental & Geotechnical Ltd., the program emphasizes engagement with Indigenous Communities to ensure environmental and cultural considerations are integrated into project planning. Gold X2 expects to complete the baseline studies by the end of 2026 and plans to enter the formal permitting process with a feasibility study in 2027. The company aims to submit both Provincial and Federal Environmental Assessment applications in the third quarter of 2027, moving the project closer to regulatory approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL7yTP6k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSL.AU","BK7067","BK7508","BK7501","BK7511"],"gpt_icon":0},{"id":"2581076953","title":"Dimerix to Benefit from Filpari's Approval, But Nothing to Lose from Rejection, Says Euroz Hartleys","url":"https://stock-news.laohu8.com/highlight/detail?id=2581076953","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581076953?lang=en_us&edition=fundamental","pubTime":"2025-11-07 15:02","pubTimestamp":1762498924,"startTime":"0","endTime":"0","summary":"If Dimerix's  US peer Travere's drug Filspari is approved by the US Food and Drug Administration, it would likely be positive for Dimerix, but the consequences would be neutral if rejected, said Euroz Hartleys in a Friday note.The research firm believes that the Filspari launch would raise awareness of focal segmental glomerulosclerosis , improve diagnosis, and establish insurance support for rare kidney disease treatments, and as doctors are expected to use Dimirex's DMX-200 together with Filspari, it could help accelerate acceptance of the medication.If the US FDA rejects Filspari, the effect would likely be neutral for Dimerix, the note added.Euroz Hartleys said that Travere's setback would stem from its trial design, not the medical need. Dimerix's own placebo-controlled study with clear goals follows a stronger regulatory path, keeping its outlook intact.Euroz Hartleys has maintained its speculative buy rating on Dimerix with a price target of AU$1.68.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FSGS","BK7508","BK7067","BK7501","DXB.AU"],"gpt_icon":0},{"id":"2581407517","title":"Mayne Pharma - Asic Formally Granted Co an Extension of Time to Hold Its 2025 AGM From on or Before 28 Nov to on or Before 30 Jan","url":"https://stock-news.laohu8.com/highlight/detail?id=2581407517","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581407517?lang=en_us&edition=fundamental","pubTime":"2025-11-07 14:44","pubTimestamp":1762497855,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nFWN3WI2RL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7096","MYX.AU"],"gpt_icon":0},{"id":"2581075106","title":"Mayne Pharma Group Ltd - Extension of Time to Hold Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2581075106","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581075106?lang=en_us&edition=fundamental","pubTime":"2025-11-07 14:44","pubTimestamp":1762497855,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nFWN3WI2RL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7096","MYX.AU"],"gpt_icon":0},{"id":"2581279510","title":"September 'Painful' Month for Long-Term Quality Growth Investors, Says BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2581279510","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581279510?lang=en_us&edition=fundamental","pubTime":"2025-11-07 13:09","pubTimestamp":1762492193,"startTime":"0","endTime":"0","summary":"September was a \"painful\" month for long-term quality growth investors in Australia as the Steady Compounder stocks underperformed by around 5.4%, said Bank of America in a Friday report.The top-ranked stocks by the triple momentum method were Evolution Mining , Northern Star , Newmont , Life360 , and Zip , the report added.The bank said that so far this year, global funds have bought the most shares in Block, Sigma Healthcare , Goodman , Northern Star Resources, and Aristocrat , while selling Newmont, Amcor , Rio Tinto , and CSL .The bank noted that the main Australian share index rose by 0.4%, while global shares gained 2.2%.The materials sector led gains, with seven of the ten best-performing stocks coming from this sector. Meanwhile, the weakest momentum was seen in energy, utilities, and health care sectors, with Yancoal , CSL, Xero , and Fisher & Paykel Health  at the bottom.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FPH.AU","ZIP.AU","AMC.AU","ALL.AU","XJO.AU","RIO.AU","BK7509","BK7506","BK7103","GMG.AU","BK7093","YAL.AU","BK7007","BK7158","BK4211","CSL.AU","ISBC","XKO.AU","BK7155","XYZ.AU","BK7099","SIG.AU","XAO.AU","BK7104","BK7511","BK7067","NST.AU","BK7508","BK7016","BK7063","EVN.AU","BK7503","BK7501","BK7083","BK7510","XRO.AU","BK7507","BK7078","NEM.AU","360.AU","BK7095"],"gpt_icon":0},{"id":"2581702433","title":"Grassroots leagues revive China's soccer dream","url":"https://stock-news.laohu8.com/highlight/detail?id=2581702433","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581702433?lang=en_us&edition=fundamental","pubTime":"2025-11-07 12:00","pubTimestamp":1762488000,"startTime":"0","endTime":"0","summary":"Grassroots leagues revive China's soccer dreamChinese soccer historically plagued by poor performances, match fixing, corruptionAmateur leagues on the rise after success of rural games played by farmers, blue-collar workersAmateur talent helps to revive China's dream of becoming soccer superpowerBy Qiaoyi Li, Josh Arslan and Tingshu Wang","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL3N3VG0DI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7511","BK7508","CSL.AU","BK7067"],"gpt_icon":0},{"id":"2581702324","title":"BRIEF-Mayne Pharma Group Updates On Status Of FIRB Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2581702324","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581702324?lang=en_us&edition=fundamental","pubTime":"2025-11-07 09:40","pubTimestamp":1762479623,"startTime":"0","endTime":"0","summary":"BRIEF-Mayne Pharma Group Updates On Status Of FIRB ApprovalNov 7 (Reuters) - Mayne Pharma Group Ltd MYX.AX:UPDATE ON STATUS OF FIRB APPROVALFIRB EXTENDS DEADLINE FOR APPROVAL TO 14 NOVEMBER 2025Further company coverage: MYX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nTUE8KKWKD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7096","MYX.AU"],"gpt_icon":0},{"id":"2581704970","title":"Mayne Pharma Group Ltd - Firb Extends Deadline for Approval to 14 November 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2581704970","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581704970?lang=en_us&edition=fundamental","pubTime":"2025-11-07 06:36","pubTimestamp":1762468601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUE8KKWKD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","MYX.AU","BK7096"],"gpt_icon":0},{"id":"2581046771","title":"High Growth Tech Stocks in Australia for November 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2581046771","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581046771?lang=en_us&edition=fundamental","pubTime":"2025-11-07 03:06","pubTimestamp":1762455965,"startTime":"0","endTime":"0","summary":"The Australian market has been navigating a period of uncertainty, with key indices fluctuating due to geopolitical events and rising inflation, while sectors like materials have shown resilience amidst these challenges. In this environment, identifying high growth tech stocks requires focusing on companies that demonstrate robust adaptability and innovation to thrive despite broader market volatility.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/high-growth-tech-stocks-in-australia-for-november-2025","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/high-growth-tech-stocks-in-australia-for-november-2025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AYA.AU","BK7503","XJO.AU","BK7016","BK7067","CUV.AU","BK7094","XAO.AU","IFM.AU","BK7508","XKO.AU"],"gpt_icon":0},{"id":"2581678190","title":"Immuron Limited Announces US$8.5 Million Share Placement to US Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2581678190","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581678190?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:11","pubTimestamp":1762431096,"startTime":"0","endTime":"0","summary":"Immuron Limited has announced a proposed issue of up to 8,495,080 ordinary fully paid shares  to US investors through its US At-The-Market  facility managed by H.C. Wainwright & Co. The facility is described as low fee and no discount. The company stated that there will be no change to its dividend or distribution policy as a result of this share issuance. The shares are expected to be issued on July 11, 2025, and the company has confirmed compliance with secondary sale provisions under Australian law through the publication of a cleansing notice.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieva","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL48sgF2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMC.AU"],"gpt_icon":0},{"id":"2581065005","title":"Haemonetics reports second quarter revenue of $327 million and earnings per diluted share of $0.81","url":"https://stock-news.laohu8.com/highlight/detail?id=2581065005","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581065005?lang=en_us&edition=fundamental","pubTime":"2025-11-06 19:01","pubTimestamp":1762426885,"startTime":"0","endTime":"0","summary":"Haemonetics Corporation reported second quarter fiscal 2026 revenue of $327 million, a decrease of 5.0 percent compared to the prior year period. Year-to-date revenue was $649 million, also down 5.0 percent. Organic revenue decreased by 1.8 percent in the quarter and 0.7 percent year-to-date. Excluding CSL, organic revenue increased by 9.4 percent in the quarter and 11.1 percent year-to-date. Earnings per diluted share were $0.81 for the quarter and $1.51 year-to-date. Adjusted earnings per diluted share were $1.27 for the quarter and $2.36 year-to-date. The company raised its total company fiscal 2026 guidance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Haemonetics Corporation published the original content used to generate this n","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL6TM5md:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z6F94.USD","CSL.AU","LU1169589451.USD","IE00BLDYK493.USD","IE0034390439.USD","LU1169590202.USD","HAE","LU0205194284.USD","BK7508","LU0106261612.USD","BK4198","LU0205193047.USD","LU0012050646.USD","BK7511","BK7067","BK7501","IE00B64QTZ34.USD"],"gpt_icon":0},{"id":"2581063159","title":"BRIEF-Australian Government Takeovers Panel Receives Application From Mayne Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2581063159","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581063159?lang=en_us&edition=fundamental","pubTime":"2025-11-06 18:29","pubTimestamp":1762424987,"startTime":"0","endTime":"0","summary":"BRIEF-Australian Government Takeovers Panel Receives Application From Mayne PharmaNov 6  - Australian Government Takeovers Panel:TOV: MYX PANEL RECEIVES APPLICATION,TOVRECEIVES APPLICATION FROM MAYNE PHARMA GROUPSITTING PANEL HAS NOT BEEN APPOINTED AT THIS STAGENO DECISION HAS BEEN MADE  WHETHER TO CONDUCT PROCEEDINGSMAYNE SEEKS INTERIM ORDERS, INCLUDING COSETTE CONFIRM TO THE PANEL THAT IT WILL MEET WITH FIRBMAYNE SEEKS FINAL ORDERS, INCLUDING COSETTE AGREE TO EXTEND STATUTORY DEADLINE FOR FIRB'S DETERMINATION TO 1 DECFurther company coverage: MYX.AX ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUE8KMLW1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","MYX.AU","BK7096"],"gpt_icon":0},{"id":"2581905572","title":"Australia's Takeovers Panel - No Decision Has Been Made  Whether to Conduct Proceedings","url":"https://stock-news.laohu8.com/highlight/detail?id=2581905572","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581905572?lang=en_us&edition=fundamental","pubTime":"2025-11-06 15:31","pubTimestamp":1762414276,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUE8KMLW1:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MYX.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2581091055","title":"Australia's Takeovers Panel - Mayne Seeks Final Orders, Including Cosette Agree to Extend Statutory Deadline for Firb's Determination to 1 Dec","url":"https://stock-news.laohu8.com/highlight/detail?id=2581091055","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581091055?lang=en_us&edition=fundamental","pubTime":"2025-11-06 15:31","pubTimestamp":1762414276,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUE8KMLW1:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7096","MYX.AU"],"gpt_icon":0},{"id":"2581055783","title":"Australian Govt Takeovers Panel - Receives Application From Mayne Pharma Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2581055783","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581055783?lang=en_us&edition=fundamental","pubTime":"2025-11-06 15:31","pubTimestamp":1762414276,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUE8KMLW1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MYX.AU","BK7508","BK7096"],"gpt_icon":0},{"id":"2581055059","title":"Australia's Takeovers Panel - Mayne Seeks Interim Orders, Including Cosette Confirm to the Panel That It Will Meet With Firb","url":"https://stock-news.laohu8.com/highlight/detail?id=2581055059","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581055059?lang=en_us&edition=fundamental","pubTime":"2025-11-06 15:31","pubTimestamp":1762414276,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUE8KMLW1:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","MYX.AU","BK7096"],"gpt_icon":0},{"id":"2581003705","title":"Proteomics International Receives AU$500,000 Western Australia Grant to Help Commercialize Endometriosis Blood Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2581003705","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581003705?lang=en_us&edition=fundamental","pubTime":"2025-11-06 14:29","pubTimestamp":1762410577,"startTime":"0","endTime":"0","summary":"Proteomics International Laboratories  received a AU$500,000 grant from the Western Australian government to accelerate the commercialization of its blood test for the early diagnosis of endometriosis, according to a Thursday Australian bourse filing.The funding was provided by the Western Australian government's Future Health Research and Innovation Fund. It will contribute to commercialization activities, including regulatory engagement, marketing, and partnership development.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["WRN","XKO.AU","BK7048","PIQ.AU","BK7508","XAO.AU","BK4168","XJO.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":1,"totalSize":163,"code":"91000000","status":"200"}]}}